Valiant Organics Ltd

Business Overview

• Valiant Organics manufactures specialty chemicals, including chlorophenol and benzene derivatives.
• Six units across five locations with total capacity of 70,000 TPA.
• Diversified client base across dyes, pigments, agrochemicals, pharmaceuticals, and veterinary products.
• Q1-FY27 highlights margin expansion and raw-material efficiency.

Operational Highlights

• Q1-FY27 consolidated revenue rose 13.3% YoY to INR 2,315 Mn.
• Gross margin improved to 43% from 39% YoY.
• Raw material cost declined to 57% of sales, saving ~INR 4 per INR 100 revenue.
• EBITDA margin expanded to 17.97%, highest in six quarters.
• PAT at INR 293 Mn; PAT margin 12.66%.
• Finance cost declined 15% YoY to INR 51 Mn.

Financial Performance

• Consolidated Q1-FY27 revenue INR 2,315 Mn; EBITDA INR 416 Mn; PBT INR 368 Mn; PAT INR 293 Mn.
• EBITDA margin 17.97%, PAT margin 12.66%.
• Standalone Q1-FY27 revenue INR 2,315 Mn; EBITDA INR 416 Mn; PAT INR 218 Mn; PBT INR 289 Mn.
• Standalone PAT margin 9.42%; consolidated EPS INR 10.44; standalone EPS INR 7.79.

Capital Structure & Liquidity

• Equity: INR 7,594 Mn; borrowings: INR 2,527 Mn (2,001 current, 526 non-current).
• Cash and cash equivalents: INR 18 Mn.

Strategic Priorities & Outlook

• Focus on margin expansion and raw-material efficiency.
• Capex and capacity utilization improvements to sustain growth.
• Maintain operating leverage to support profitability.

ESOP grant details

• NRC approved grant of 18,000 ESOPs under the ESOP Scheme 2022.
• Exercise price fixed at Rs 10 per option.
• Options exercisable for 3 years from vesting.
• Vesting details: currently no options vested.
• Total shares underlying: 18,000 equity shares.
• Options not yet exercised; no money realized.
• Conversion ratio: one option yields one share.
• Regulatory framework: SBEB Regulations 2021 compliance.
• Program administered by NRC; subject to eligibility criteria.
• Diluted EPS impact pending upon exercise.

Managing Director re-appointment

• Re-appointment of Shri Sathiababu K. Kallada as MD for 24 May 2027 to 23 May 2030.
• Profile: BSc; 38+ years in chemical industry; prior roles in leading speciality chemicals.
• Subject to shareholder approval at the ensuing AGM.
• Not debarred by SEBI or other authorities.

Meeting Details

• Board meeting on August 12, 2026; time and venue not disclosed.

Key Agenda Items

• Consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
• Any other business matters, if required with chair's permission.

Other Notes

• Trading window closed until August 14, 2026 for the aforesaid purposes.

Dematerialisation status

• Regulation 74(5) not applicable; all securities are dematerialised; no dematerialisation/rematerialisation requests received.